Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Recruiting Phase 3 Interventional

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

NCT07227818
View directory record Official record
Conditions
Schizophrenia
Interventions
NBI-1117568, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Garden Grove, California • La Habra, California • Lemon Grove, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Phase 1 Interventional

Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia

NCT00601224
View directory record Official record
Conditions
Schizophrenia
Interventions
Social cognition and interaction training (SCIT), Treatment as usual (TAU)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

NCT02824666
View directory record Official record
Conditions
Schizophrenia
Interventions
ATI-9242, [18F]Fallypride Imaging
Drug · Radiation
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Phase 4 Interventional Results available

Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia

NCT01010477
View directory record Official record
Conditions
Smoking Cessation, Schizophrenia
Interventions
Nicotine Nasal Spray, Behavioral counseling
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia

NCT00560937
View directory record Official record
Conditions
Schizophrenia
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01490086
View directory record Official record
Conditions
Acute Schizophrenia, Schizoaffective Disorder
Interventions
RP5063, placebo, aripiprazole
Drug
Lead sponsor
Reviva Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 24, 2026, 2:30 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Phase 1 Interventional

Social Cognitive Training for Psychosis: Treatment Development

NCT01579422
View directory record Official record
Conditions
Schizophrenia, Psychosis
Interventions
social cognitive training
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 24, 2026, 2:30 AM EDT
Terminated Phase 2 Interventional Results available

A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia

NCT03900754
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 24, 2026, 2:30 AM EDT
Completed No phase listed Observational

Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

NCT03919994
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
57
States / cities
Tucson, Arizona • Costa Mesa, California • El Cajon, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 24, 2026, 2:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiological Studies in Schizophrenia and Psychiatric Disorders

NCT01384604
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
15 Years to 70 Years
Enrollment
1,189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 24, 2026, 2:30 AM EDT
Terminated Phase 4 Interventional

Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

NCT00169091
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine, Haloperidol
Drug
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Not applicable Interventional Results available

Improving Accessibility and Personalization of CR for Schizophrenia

NCT03576976
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Remediation
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Brooklyn, New York • New York, New York • Orangeburg, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neuroplasticity in TBI and Schizophrenia

NCT03995368
View directory record Official record
Conditions
Schizophrenia, Traumatic Brain Injury
Interventions
Electroencephalography
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
25 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 2:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Symptomatology and Treatment Response in Psychotic Major Depression

NCT00691535
View directory record Official record
Conditions
Psychotic Disorders, Depressive Disorder, Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Not applicable Interventional Results available

Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation in Schizophrenia

NCT02975973
View directory record Official record
Conditions
Schizophrenia, Psychosis
Interventions
transcranial direct current stimulation
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Phase 2 Interventional

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

NCT00968851
View directory record Official record
Conditions
Schizophrenia, Central Nervous System Diseases, Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
14
States / cities
Glendale, California • Oceanside, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Not applicable Interventional

Feasibility Trial of a Lifestyle Intervention for CHR-P

NCT05532683
View directory record Official record
Conditions
Prodromal Schizophrenia, Psychosis, Psychological Disorder, Psychological Stress
Interventions
Health Behaviors Group
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Phase 4 Interventional Results available

Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation

NCT00628394
View directory record Official record
Conditions
Cognition in Schizophrenia
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls

NCT01214005
View directory record Official record
Conditions
Tobacco Use Disorder, Schizophrenia
Interventions
smoking abstinence
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

NCT01289080
View directory record Official record
Conditions
Schizophrenia, Psychiatric Disorders
Interventions
OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Not applicable Interventional Results available

Reducing Cardiovascular Risk in Adults With Serious Mental Illness

NCT02451670
View directory record Official record
Conditions
Chronic Disease, Mental Disorder, Health Behavior, Bipolar Disorder, Schizophrenia
Interventions
Prioritized Clinical Decision Support
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
10,347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Duluth, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cariprazine in Schizophrenia

NCT01104779
View directory record Official record
Conditions
Schizophrenia
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Costa Mesa, California • Long Beach, California • Paramount, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 24, 2026, 2:30 AM EDT
Completed Phase 1 Interventional

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

NCT04010305
View directory record Official record
Conditions
Agitation, Schizophrenia
Interventions
Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 2:30 AM EDT